home / stock / auph / auph news


AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/19/24

Stock Information

Company Name: Aurinia Pharmaceuticals Inc
Stock Symbol: AUPH
Market: NASDAQ
Website: auriniapharma.com

Menu

AUPH AUPH Quote AUPH Short AUPH News AUPH Articles AUPH Message Board
Get AUPH Alerts

News, Short Squeeze, Breakout and More Instantly...

AUPH - AUPH, PSNV and VNDA are among after hour movers

2024-01-19 16:55:57 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +5% . Edgewise Therapeutics ( EWTX ) +3% . Rush Enterprises ( RUSHA ) +2% . Cricut ( CRCT ) +2% . EchoStar Corporation ( SATS ) +2% . Losers: Fusion Pha...

AUPH - (AUPH) Long Term Investment Analysis

2024-01-06 06:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

AUPH - Aurinia Pharmaceuticals sees strong Q4 revenue growth, eyes cash flow positivity

2024-01-05 07:27:02 ET More on Aurinia Pharma Aurinia Pharmaceuticals: A Post Q3 Earnings Assessment Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript Aurinia Pharma goes negative even amid takeover speculation Aurinia partner files for Jap...

AUPH - Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results

Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and full year 2023 of approximately $42 million and $159 million Approximately $351 mill...

AUPH - Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Upon FDA clearance of the IND, AUR 200 will be studied in a Phase 1 first-in-human trial in healthy v...

AUPH - Aurinia Pharmaceuticals: A Post Q3 Earnings Assessment

2023-12-07 11:16:36 ET Summary Today, we circle back on promising biopharma Aurinia Pharmaceuticals Inc. The company posted better-than-expected Q3 results and has been the subject of more buyout speculation, and had its marketing partner file for approval in Japan for its flagshi...

AUPH - Aurinia Pharmaceuticals Inc ($AUPH) Trading Report

2023-11-23 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

AUPH - Aurinia Pharma jumps amid takeover speculation

2023-11-21 10:30:55 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) soared 6.7% amid takeover speculation. The Aurinia ( AUPH ) stock surge comes amid a report that a Gilead Sciences ( GILD ) corporate jet made a trip to Aurinia's headquarters in Edmonton, Canada, accord...

AUPH - Aurinia partner files for Japan approval of lupus nephritis drug

2023-11-13 07:11:13 ET More on Aurinia Pharma Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia Pharma s...

AUPH - Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labo...

Previous 10 Next 10